GlassScriptPhysician profile
Darren Ballard
NPI 1467652560
$2,306.62
in general payments reported to CMS, 2019-2025
27 companies · $356 in 2025
The $356 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $934 · 2020: $318 · 2022: $240 · 2023: $99.73 · 2024: $358 · 2025: $356.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $814.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $813.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $437.94 | 2019-2025 | |
| Janssen Biotech, INC. | $364.19 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $245.68 | 2019-2025 | Eohilia, Entyvio |
| Boston Scientific Corporation | $197.27 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $153.70 | 2019-2020 | |
| Shionogi INC | $124.67 | 2019-2020 | |
| Gilead Sciences, INC. | $95.65 | 2023-2024 | |
| Qol Medical, LLC | $57.78 | 2019-2024 | Sucraid |
| Allergan, INC. | $56.41 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $53.96 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $52.57 | 2024-2025 | Omvoh |
| Ardelyx, INC. | $52.22 | 2023-2024 | Ibsrela |
| Endogastric Solutions, INC | $50.47 | 2020 | |
| Ironwood Pharmaceuticals, INC | $43.44 | 2019-2020 | |
| Biocon Biologics INC | $39.94 | 2025 | Yesintek |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $38.87 | 2023 | Zeposia |
| Merck Sharp & Dohme LLC | $37.09 | 2019-2020 | |
| Pfizer INC. | $36.80 | 2019-2022 | |
| Genzyme Corporation | $30.93 | 2024 | |
| Covidien LP | $29.02 | 2019 | |
| Amgen INC. | $27.14 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $21.69 | 2025 | Iqirvo |
| Daiichi Sankyo INC. | $19.15 | 2020 | |
| Braintree Laboratories, INC. | $14.87 | 2020 | |
| Echosens North America, INC. | $14.03 | 2025 | Fibroscan |
| Shire North American Group INC | $11.14 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$11,338.54 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darren Ballard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.